Ready, set, GO? Treating older adults with AML
Abstract
In this issue of Blood, Knapper et al 1 report the results of a large, randomized trial of daunorubicin and cytarabine with 2 doses of gemtuzumab ozogamicin (GO; DAGO2) vs CPX-351 in older adults with acute myeloid leukemia (AML) without adverse cytogenetics.The original primary end point of the study was overall survival (OS).However, because of accrual being affected by the COVID-19 pandemic, the primary end point was changed to event-free survival (EFS), with an event being defined as resistance to treatment (refractory disease or partial response after course 2), relapse, or death.
Fields of Study & Subjects
Acute Myeloid Leukemia Research
Retinoids in leukemia and cellular processes
Chronic Myeloid Leukemia Treatments
Publication details
- Journal / source
- Blood
- Volume
- 147
- Issue
- 10
- Pages
- 1007–1008
- Publication date
- 5 March 2026
- Language
- EN